DIA EUROPE 2021

Back to Agenda

How Can We Address AMR “Broken Business Model” to Activate Antibacterial R&D? Policy Needs, Potential Solutions and Examples

Session Chair(s)

Keiko Tone, MBA

VP EU Market Access and Policy

Shionogi, United Kingdom

Pull incentives for antibacterial R&D are needed imminently, as pipeline is drying out and companies continue exiting this area. Industry, clinicians, academia and authorities discuss the issues, potential solutions and examples of new incentives.

Learning Objective : • Recognise the AMR policy needs for pull incentives to stimulate antibacterial R&D • Contrast the different cost to achieve a cure for antibacterials and other curative therapies such as treatments for oncology and hepatitis C • Discuss different options for incentivising R&D and access to antibacterials • Share practical example/s implemented to improve antibacterial access

Speaker(s)

Cost of Cure – Analysis of Difference by Disease Area

Claudio Jommi, MSc

SDA Bocconi School of Management, Italy

Professor of Practice at SDA Bocconi

Antibiotic Challenges and Way Forward – Broken Business Model and HTA Approach

Lotte Steuten, PhD, MS

Office of Health Economics, United Kingdom

Vice President, Head of Consulting

Implementation of New Incentives for Antibiotics – Example from England

David Glover

NHS England and NHS Improvement, United Kingdom

General Manager

Have an account?